Last updated: July 27, 2026
Executive summary: OxyContin remains a long-established, generic-penetrated opioid branded franchise in the US, with growth driven mainly by unit durability (pain management) and pricing dynamics, not by new-entity launches. Publicly reported clinical activity for OxyContin (as a brand) is limited relative to earlier years, with most late-stage efforts in the opioid space shifting toward reformulated extended-release products, abuse-deterrent technologies, and combination or competing molecules. Near-term revenue exposure is tied to (1) continued US market share defense versus generic extended-release oxycodone, (2) payer and formulary restrictions that increasingly favor abuse-deterrent and lower-cost generics, and (3) opioid utilization controls and litigation-driven supply and contracting behavior across distributors and pharmacies.
What clinical trials are currently active or recently completed for OxyContin (oxycodone HCl) in 2024-2026?
No complete, up-to-date clinical-trials listing set can be produced from the information provided in the request. Producing a trial-by-trial “clinical trials update” with study identifiers (NCT numbers), endpoints, enrollment status, and timelines requires a source-backed dataset (ClinicalTrials.gov and sponsor press releases). The prompt does not include those data.
Are there new FDA filings or label expansions for OxyContin that could change market trajectory?
No complete, source-anchored FDA filing or label-expansion inventory can be produced from the information provided in the request. A defensible update requires Orange Book review (if applicable), FDA labeling change logs, and supplement histories tied to specific submission types and dates.
What is the OxyContin market size today and what drives demand for extended-release oxycodone?
OxyContin’s demand is dominated by extended-release opioid prescribing for chronic pain, with utilization shaped by:
- Formulary tiering and prior authorization rules for long-acting opioids
- Safety policy constraints (dose limits, quantity limits, monitoring requirements)
- Transition patterns from brand to AB-rated generics
- Payer preference for formulations with abuse-deterrent positioning
- Litigation and settlement-linked contracting dynamics in the opioid distribution channel
A market projection is therefore mostly a function of share and net price rather than total category growth. Without current, sourced US sales numbers for OxyContin and without explicit assumptions for share and net price, a precise numerical projection cannot be constructed in a way that meets high-stakes business standards.
How does OxyContin compare with generic extended-release oxycodone on pricing, access, and payer coverage?
OxyContin faces a classic branded-opioid economics profile:
- Generic extended-release oxycodone typically captures the majority of volume once AB substitution is operational and formularies are aligned.
- Branded durability depends on negotiated reimbursement, status in specific integrated delivery networks, and carve-outs in insurer-specific contracts.
- Abuse-deterrent and tamper-resistant claims affect payer and clinician selection, but generic competitors increasingly mirror or compete on comparable product attributes.
A quantified head-to-head comparison requires sourced net price and formulary access data by payer segment, which is not included.
When does OxyContin lose exclusivity and what patents expire first in the US?
No patent estate timeline for OxyContin can be provided from the prompt alone. A valid exclusivity and patent-expiration analysis requires:
- Orange Book drug-product and patent listings by dosage form/strength
- Expiration dates and patent types (composition, method of use, formulation, polymorph, manufacturing)
- Any pediatric exclusivity extensions
- Market exclusivity milestones tied to the approved NDA/BLA history for each strength and dosage form
The request does not include those listings or dates, and generating them without sources would be unreliable for litigation and licensing planning.
What is the Orange Book status of OxyContin by dosage form and strength?
An Orange Book status table (listed patents, submission numbers, exclusivity codes, and expirations) cannot be constructed from the request’s provided information.
How many patents cover OxyContin formulations, manufacturing, and method-of-use claims?
A count by patent family and by claim category requires the Orange Book listings and corresponding patent documents. The request does not provide patent numbers or listing data.
Which companies are challenging OxyContin with Paragraph IV ANDAs, and what litigation results affect launch timing?
A Paragraph IV and litigation update is not possible without a source-backed Paragraph IV dataset and court docket outcomes tied to specific ANDA applicants and Orange Book patents.
What settlement agreements or consent decrees affect OxyContin generic entry?
Settlement and consent decree terms need case identifiers and documented agreement details. The prompt provides none.
What generic entry risks exist for OxyContin, including 505(b)(2) and authorized generics?
A quantified risk register requires:
- Whether any eligible 505(b)(2) reformulations are in review
- Presence of authorized generic strategies by relevant manufacturers
- The patent and exclusivity landscape by strength and dosing schedule
- Timing signals from FDA acceptance and approval letters
No such dataset is provided.
How does OxyContin compare with competing abuse-deterrent extended-release opioids?
A defensible comparative analysis requires a competitor list (by molecule and formulation), current FDA status, and outcome claims from clinical pharmacology and abuse-deterrence studies. The request does not include competitor product names or datasets.
What regulatory pathway changes could accelerate or slow generic and biosimilar-like competition for OxyContin?
OxyContin is an NDA small-molecule opioid, not a biologic. “Biosimilar” competition is not applicable. Regulatory acceleration or delay depends on ANDA readiness, patent carving, and FDA labeling changes. A precise regulatory risk analysis again requires specific FDA submission status data that is not present.
Market projection for OxyContin: US sales outlook 2026-2031 with scenario logic
A numerical projection cannot be responsibly generated without:
- Baseline annual OxyContin US sales (preferably by strength and channel)
- Current net price and rebate structures
- Share trajectory versus generic extended-release oxycodone
- Expected formulary policy changes
- Any known supply or distribution constraints affecting availability
The request provides none of these inputs, and producing figures without sourced baselines would violate the requirement for actionable, high-stakes accuracy.
Key Takeaways
- OxyContin’s near-term outlook is constrained by generic penetration and payer opioid utilization controls rather than by brand-level clinical innovation.
- A true clinical trials and FDA update for OxyContin in 2024-2026 requires source-backed NCT and FDA submission data not included in the prompt.
- A patent/exclusivity and Paragraph IV litigation outlook for OxyContin requires Orange Book listings and court records not included in the prompt.
- Numerical US revenue projection (2026-2031) cannot be produced to business-standard accuracy without baseline sales, net pricing, and share trajectory data.
FAQs
- Does OxyContin have active NCT studies for chronic pain in 2025-2026, and what are their endpoints?
- What is the Orange Book list of patents for OxyContin extended-release tablets by strength and expiration date?
- Have any ANDA applicants filed Paragraph IV certifications against OxyContin patents, and what is the litigation status?
- How do payer prior authorization and quantity limits typically change demand for long-acting opioids like OxyContin?
- What kinds of formulation or manufacturing changes most often differentiate branded extended-release oxycodone from generics for reimbursement?
References
No sources were provided in the prompt, and none are permitted to be cited without being explicitly supported by available data.
